卫材株式会社与复宏汉霖宣布，双方已正式签署一项独家商业化许可协议。根据协议条款，卫材将获得抗PD-1抗体斯鲁利单抗在日本市场的独家商业化权利。这一合作旨在加速该创新免疫疗法在日本的上市进程，为当地患者提供新的治疗选择。双方将整合各自在研发与商业化领域的优势资源，共同推进斯鲁利单抗的临床开发与市场准入工作。
卫材株式会社与复宏汉霖宣布，双方已正式签署一项独家商业化许可协议。根据协议条款，卫材将获得抗PD-1抗体斯鲁利单抗在日本市场的独家商业化权利。这一合作旨在加速该创新免疫疗法在日本的上市进程，为当地患者提供新的治疗选择。双方将整合各自在研发与商业化领域的优势资源，共同推进斯鲁利单抗的临床开发与市场准入工作。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.